News | February 20, 2022
Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Biogen paid Ionis a US $ 60 million one-time upfront payment
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Anti-malaria API facility will be operational in 15-18 months
Subscribe To Our Newsletter & Stay Updated
